You're kidding right? News flash: unless you have a massive market cap with hugely accretive revenues, earnings do count...big time. No way the stock retains this value unless they demonstrate earnings progress.
absurd isn't it! I'm sure that if your average share cost higher than current levels then the haircut hurts. But I would question their investment savvy--know when to hold or fold. I added yesterday.
Sorry man, I will place my bets with a recognized world-class leader in pharma. therapeutics than with you. Especially since you obviously don't understand the paradigm brings to the medicine.
I used today for a buying opportunity. Read the conference call notes. 2016 will be a solid year with new test programs, greater volumes and likely Medicare reimbursements.
Interesting how if your average sp cost is $10 or lower than the world is your oyster. The sky is the limit for this stock. Who can find fault with that. IMO though, we're seeing full valuation minus any set back in approvals or general market value destruction. Those with a sizeable holding would be wise to take some off the table and wait.
Obviously, in your class you didn't cover the topics of RONA and accretive sales growth/capex . For GLW the metrics aren't good.
who cares! It boils down to if you believe that the sp is fully valued, fairly-valued or over-valued. Whatever you did or didn't do has zero relevance on our investment decisions.
Well aren't you special! Careful how you gloat. The fickle finger of fate has a way of changing everything. Consider if the good Dr passes-on even a sound succession plan will have little effect on the sp getting crushed. Much of the current pricing is based on his reputation.
Then either an inadvertent misquote or misconstrued. FMI is targeted therapy concern focused on cancer therapies. "GeneDx specializes in genetic testing for rare hereditary disorder."
Miami, that's from the GeneDX website. Foundation Medicine is world-class targeted therapy partner for cancer thus Roche picked up over 50% of the shares. GeneDX is just a testing lab
K9, for the most part I agree with your comments. However youi are totally wrong about the recent Roche deal. The business model of FMI is not remotely similar to that of GeneDX.
Brilliant (not) You could have ADD and a disciple of the buy high and sell low school.
you are correct. The big fish got their fill and now looking for other tidbits to feast on.
Ask yourself this question: Why didn't Roche devour the whole enchilada? Was it because they wanted control of the data for themselves for the most part.
$30/share is my guess
IMO your thesis that the share price is less vulnerable after the Roche infusion fails to appreciate how the VC's see the future now. They are bailing because in the end a partnership is a sinking ship. $30 is my "Guess."
Another factor is the VC's winding down their positions. Which should say to investors that the sp upside is constrained.
The value of this company imo is the ip, not so much as their earnings potential. Roche wanted their data base for their use own before a competitor gobbled them. I don't believe we will see $50 again.